AI Oncology Expansion Avenda Health’s Unfold AI is FDA-cleared and now deployed across the entire prostate cancer care continuum, signaling opportunities to upsell integrated AI solutions to hospital systems expanding cancer care capabilities.

New Health Network Wins Recent deployments at University of Michigan Health and ongoing expansion in the Midwest indicate a pattern of hospital network adoption, suggesting target accounts include large academic centers and regional health systems seeking AI-enabled prostate cancer care.

Awarded credibility Recognition from Digital Health Awards and HLTH enhances credibility with healthcare buyers, easing procurement conversations and helping position Unfold AI as a trusted, innovative solution in competitive RFPs.

Robotic AI Focal The launch of AI-assisted Focal One robotic HIFU procedures demonstrates capability in advanced interventional treatments, presenting cross-sell opportunities to centers performing or expanding focal therapies and image-guided interventions.

Growth Momentum With a 25–50 million revenue range and $19 million in funding, Avenda Health is in a growth phase; engage financially focused stakeholders to explore scale deals, multi-site purchases, and potential partnerships with health systems investing in AI-enabled cancer care.